Food industry vets commence new lobbying practice
WASHINGTON Policy Solutions, a new government and public affairs firm, has opened a practice in Washington, led by three food industry veterans.
The new firm will provide strategic advice to its clients and assistance in coalition building, grassroots program development, media relations, and in community outreach and corporate responsibility programs.
The three principals of the lobbying group include John Motley, former SVP government affairs for the Food Marketing Institute; Barry Scher, former long-time VP public affairs for Giant Foods; and Jay Truitt, former VP government affairs for the National Cattlemen’s Beef Association.
“With both a new Congress and administration, there will be increased legislative and regulatory activity. Policy Solution’s principals have an extensive experience in working with both Congress and the Executive Branch on a wide range of policy issues, from food safety to energy and from taxes to health care,” said Motley.
For more information on this group, visit policy-solutions.net.
Taro files patent infringement suit against three companies
HAWTHORNE, N.Y. An Israeli generic drug maker has sued three other companies, alleging patent infringement.
Taro Pharmaceutical Industries announced Monday that it had filed suit in the U.S. District Court for the District of New Jersey against Synerx Pharma, DPT Labs and Karalex Pharma, alleging infringement of U.S. Patent No. 7,560,445. The patent covers Taro’s Ovide (malathion) lotion in the 0.5% strength, a treatment for head lice.
Taro said the defendants’ generic versions of the drug infringed its patent, and it’s seeking injunctive relief and damages.
News article calls Mylan’s quality control into question; company responds
PITTSBURGH A news article published over the weekend calling generic drug maker Mylan’s manufacturing into question has drawn a response from the company.
The Pittsburgh Post-Gazette reported Sunday that workers at the company’s Morgantown, W.Va., plant overrode drug quality controls required by the government by ignoring and deleting computer warnings of possible drug quality or equipment problems, based on a confidential internal report obtained by the newspaper’s reporters that called it a “pervasive” problem. Normally the warnings, known as “red screens,” require production to halt until a quality-control agent can investigate the matter.
The company responded by saying in a statement Monday that the Post-Gazette article was based on anonymous sources, improperly obtained documents and third-party commentary.
“Our customers and stakeholders can rest assured that whenever there is even the slightest departure from [a standard operating procedure], it will be dealt with immediately and effectively,” the company said in a statement. “This issue had no impact on the quality of our product.”